ICICI Securities maintains an Add call on Alkem Laboratories, revising the target price to Rs 5,900. The brokerage anticipates a revenue CAGR of 9.3% and a slight margin expansion for Alkem over the next few years. However, they have reduced EPS estimates for FY27E due to an anticipated higher tax rate, impacting valuation.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets